This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Statins Market To 2018 - Weak Product Pipeline And Shift Of Focus Towards Combination Therapies Will Lead To Erosion Of Brand Share

Table of Contents

1 Table of Contents 51.1 List of Tables 71.2 List of Figures 72 Statins Market to 2018 - Introduction 83 Statins Market to 2018 - Global Statins Market 93.1 Introduction 93.2 Global Market Forecast 103.2.1 Branded and Generic Market Share 123.3 Annual Cost of Treatment 133.4 Treatment Usage Patterns 143.4.1 Disease Population 153.4.2 Treatment Seeking Population 153.4.3 Diagnosed Population 153.4.4 Prescription Population 153.5 Drivers and Restraints to the Statins Market 163.5.1 Drivers to the Statins Market 163.5.2 Restraints to the Statins Market 173.6 Major Marketed Products 193.6.1 Crestor (rosuvastatin calcium) 193.6.2 Lipitor (atorvastatin calcium) 203.6.3 Vytorin (ezetimibe/simvastatin) 213.6.4 Zocor (simvastatin) 223.6.5 Livalo (pitavastatin calcium) 223.6.6 Lescol XL (fluvastatin sodium) 233.6.7 Pravachol (pravastatin sodium) 244 Statins Market to 2018 - Statins Market in the US 254.1 Market 254.2 Annual Cost of Therapy (ACT) 274.3 Treatment Usage Pattern 284.3.1 Diseased Population 294.3.2 Treatment Seeking Population 294.3.3 Diagnosed Population 294.3.4 Patients on Statins Therapy 295 Statins Market to 2018 - Statins Market in the Top Five Countries of Europe 305.1 Market 305.2 Annual Cost of Therapy 335.3 Treatment Usage Pattern 345.3.1 Diseased Population 355.3.2 Treatment Seeking Population 355.3.3 Diagnosed Population 355.3.4 Patients on Statins Therapy 356 Statins Market to 2018 - Statins Market in Japan 366.1 Market 366.2 Annual Cost of Therapy 386.3 Treatment Usage Pattern 406.3.1 Diseased Population 416.3.2 Treatment Seeking Population 416.3.3 Diagnosed Population 416.3.4 Patients on Statins Therapy 417 Statins Market to 2018 - Product Pipeline Anlaysis 427.1 Introduction 427.2 Pipeline Analysis 428 Statins Market to 2018 - Competitive Landscape 438.1 Pfizer Inc. 448.1.1 Company Overview 448.1.2 SWOT Analysis 448.2 AstraZeneca PLC (AstraZeneca) 458.2.1 Company Overview 458.2.2 SWOT Analysis 458.3 Merck & Co Inc 468.3.1 Company Overview 468.3.2 SWOT Analysis 468.4 Novartis AG (Novartis) 478.4.1 Company Overview 478.4.2 SWOT Analysis 479 Statins Market to 2018 - Strategic Consolidation 489.1 Merger and Acquisition (M&A) Deals 489.2 Licensing Deals 499.2.1 Licensing Deals by Geography 499.3 Co-development Deals 5110 Statins Market to 2018 - Appendix 5210.1 Market Definitions 5210.2 Abbreviations 5210.3 Bibliography 5510.4 Research Methodology 5610.4.1 Coverage 5610.4.2 Secondary Research 5610.4.3 Primary Research 5710.4.4 Therapeutic Landscape 5710.4.5 Geographical Landscape 6010.4.6 Pipeline Analysis 6010.4.7 Competitive Landscape 6010.5 Expert Panel Validation 6010.6 Contact Us 6010.7 Disclaimer 60

List of Tables

Table 1: Statins Market, Global, Revenue ($bn), 2004-2011 10Table 2: Statins Market, Global, Revenue Forecast ($bn), 2011 -2018 10Table 3: Statins Market, Global, ACT ($), 2004-2011 13Table 4: Statins Market, Global, ACT ($), 2011-2018 13Table 5: Statins Market, Global, Treatment Usage Patterns (million), 2004-2011 14Table 6: Statins Market, Global, Treatment Usage Patterns (million), 2011-2018 14Table 7: Statins Market, the US, Revenue ($bn), 2004-2011 25Table 8: Statins Market, the US, Revenue Forecast ($bn), 2011-2018 25Table 9: Statins Market, the US, ACT ($), 2004-2011 27Table 10: Statins Market, the US, ACT ($), 2011-2018 27Table 11: Statins Market, the US, Treatment Usage Pattern (million), 2004-2011 28Table 12: Statins Market, the US, Treatment Usage Pattern (million), 2011-2018 28Table 13: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 31Table 14: Statins Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 31Table 15: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2011 33Table 16: Statins Market, Top Five Countries of Europe, ACT ($), 2011-2018 33Table 17: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2011 34Table 18: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011-2018 34Table 19: Statins Market, Japan, Revenue ($bn), 2004-2011 36Table 20: Statins Market, Japan, Revenue Forecast ($bn), 2011-2018 36Table 21: Statins Market, Japan, ACT ($), 2004-2011 38Table 22: Statins Market, Japan, ACT ($), 2011-2018 38Table 23: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2011 40Table 24: Statins Market, Japan, Treatment Usage Pattern (million), 2011-2018 40Table 25: Statins Market, Global, Product Pipeline, 2012 42Table 26: Statins Market, M&A Deals ($m), 2008-2011 48Table 27: Statins Market, Licensing Deals, 2005-2011 49Table 28: Statins Market, Co-Development Deals, 2005-2008 51

List of Figures

Figure 1: Statins Market, Global, Revenue ($bn), 2004-2018 10Figure 2: Statins Market, Global, Generic and Branded Market Share (%), 2011 and 2018 12Figure 3: Statins Market, Global, ACT ($), 2004-2018 13Figure 4: Statins Market, Global, Treatment Usage Patterns (million), 2004-2018 14Figure 5: Statins Market, Global, Drivers and Barriers, 2011 16Figure 6: Statins Market, the US, Revenue ($bn), 2004 -2018 25Figure 7: Statins Market, the US, ACT ($), 2004-2018 27Figure 8: Statins Market, the US, Treatment Usage Pattern (million), 2004-2018 28Figure 9: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018 31Figure 10: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2018 33Figure 11: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2018 34Figure 12: Statins Market, Japan, Revenue ($bn), 2004-2018 36Figure 13: Statins Market, Japan, ACT ($), 2004-2018 38Figure 14: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2018 40Figure 15: Statins Market, Global, Top Companies' Market Share (%), 2011 43Figure 16: Statins Market, Pfizer Inc., SWOT Analysis, 2011 44Figure 17: Statins Market, AstraZeneca, SWOT Analysis, 2011 45Figure 18: Statins Market, Merck & Co. Inc., SWOT Analysis, 2011 46Figure 19: Statins Market, Novartis, SWOT Analysis, 2011 47Figure 20: Statins Market, Strategic Consolidation, 2005-2011 48Figure 21: GBI Research Market Forecasting Model 59

Companies Mentioned

Pfizer Inc.AstraZeneca PLC (AstraZeneca)Merck & Co Inc Novartis AG (Novartis)

To order this report: Drug_and_Medication Industry: Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

__________________________Contact Nicolas: nicolasbombourg@reportlinker.comUS: (805)-652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,077.50 +47.29 0.26%
S&P 500 2,091.95 +10.07 0.48%
NASDAQ 4,814.7860 +41.3140 0.87%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs